DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Teriflunomide (Aubagio) (Multiple Sclerosis) (Wave 4) 2013

BioTrends Research Group is pleased to announce the continuation of the syndicated report series, LaunchTrends®: Aubagio, in 2013. This four-wave primary research study will follow the launch of Aubagio by Genzyme, a Sanofi company. Waves 1 through 4 track the introduction of Aubagio based on data collected at one month, three months, six months and one year post-Aubagio launch.
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products through one year postlaunch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products. And, they capture the promotional messages and activities of key market players, as well as counter-detailing by competitors.

Questions Answered in This Report:

  • Measure awareness of and familiarity with Aubagio among neurologists

  • Understand the perceived clinical advantages and disadvantages of Aubagio compared to other marketed agents used in treating MS

  • Understand where Aubagio is expected to fit in the treatment algorithm for MS patients

  • Track the trial, adoption, and prescribing trends including anticipated trends for the treatment of MS

  • Collect information on the promotional messages and activities being employed by Genzyme


Sample Frame & Methodology:

- Waves 1 through 3 will include responses from a random sample of ~75 neurologists unique to each wave; Wave 4 may include a subset of previous respondents for a total of ~100 neurologists

- A qualitative follow-up arm includes telephone interviews conducted with a subset of ~15 survey respondents

To qualify, respodents must meet the following criteria:

- In practice between 2 and 35 years

- Minimum of 20 patients with relapsing remitting multiple sclerosis (RR-MS) under management

- Treat at least some of their RR-MS patients with DMA therapy

- More than 75% of time spent in clinical practice


- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics and standard cross tabulations

- Transcripts of qualitative interviews can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

- Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tecfidera, Tysabri

Report Dates:

- Publish:

- Wave 1: December 2012

- Wave 2: February 2013

- Wave 3: May 2013

- Wave 4: November 2013

Physician Research:

- Neurologists


- United States

Related Reports:

- TreatmentTrends®: Multiple Sclerosis (US)

- TreatmentTrends®: Multiple Sclerosis (EU)

- LaunchTrends®: Tecfidera (US)

- DecisionBase®: Multiple Sclerosis-Relapsing Remitting

- DecisionBase®: Multiple Sclerosis-Chronic Progressive

- PatientBase®: Multiple Sclerosis in Mexico

- PatientBase®: Multiple Sclerosis in Turkey

- PatientBase®: Multiple Sclerosis in South Korea

- Treatment Algorithms®: Multiple Sclerosis

- Physician and Payer Forum®: Multiple Sclerosis

- Pharmacor®: Multiple Sclerosis